Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Fitzroy Dawkins"'
Autor:
Virtue, Erica
Publikováno v:
Jamaica Gleaner; 6/30/2024, Vol. 85 Issue 26, pA2-A2, 1p
Autor:
Maanasa Gowda, Franco Locatelli, Tommaso Stefanelli, Norbert Hollaender, Shahrukh K. Hashmi, Robert Zeiser, Mary E.D. Flowers, Fitzroy Dawkins, Ronjon Chakraverty, Stephanie J. Lee, Nicola Polverelli, Takanori Teshima, Ron Ram
Publikováno v:
Blood. 136:22-24
BACKGROUND Standard first-line treatment of cGVHD includes systemic corticosteroids; however, about 50% of patients (pts) are steroid refractory or dependent (SR/D) and require additional treatment. The best second-line therapy option has not yet bee
Autor:
Michael D. Howell, Miguel-Angel Perales, Madan Jagasia, Fitzroy Dawkins, Salman Fazal, Laura Connelly-Smith, Nirav N. Shah, Haris Ali, Yi-Bin Chen, Michael C. Arbushites, H. Jean Khoury, Mark A. Schroeder, Chuan Tian
Publikováno v:
Blood. 135(20)
Patients who develop steroid-refractory acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation have poor prognosis, highlighting an unmet therapeutic need. In this open-label phase 2 study (ClinicalTrials.gov iden
Autor:
Herbert Hurwitz, Vaibhav Sahai, Chris Verslype, Jason Clark, Johanna C. Bendell, Ashwin Reddy Sama, Eric Van Cutsem, Manuel Hidalgo, Edward W Greeno, Eileen M. O'Reilly, Chung Pin Li, Kenneth H. Yu, Christopher James Walker, Fitzroy Dawkins, Teresa Macarulla, Marcelo Garrido Salvo
Publikováno v:
Investigational New Drugs. 36:683-695
Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP]
Publikováno v:
PLoS Medicine, Vol 1, Iss 2, p e51 (2004)
Externí odkaz:
https://doaj.org/article/1ed998a1e95b47d6a87c5a153743d5e5
Autor:
Fitzroy Dawkins, Andres Forero-Torres, William Jeffery Edenfield, Justin Call, Li Zhou, Daniel O. Persky, Paolo Caimi, Xuejun Chen, Swaminathan P. Iyer, Carolina Escobar, Abdulraheem Yacoub, Michael S. Wertheim, Douglas J DeMarini, Radhakrishnan Ramchandren, Martin Gutierrez, Luke P. Akard, Tycel Phillips
This phase 1/2 study assessed parsaclisib (INCB050465), a next-generation, potent, and highly selective phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, in patients with relapsed or refractory B-cell malignancies, alone or in combination with a J
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcecfa88ad0f4c321ee1122db18dc82d
https://europepmc.org/articles/PMC6543513/
https://europepmc.org/articles/PMC6543513/
Autor:
Madan Jagasia, Nirav N. Shah, Yi-Bin Chen, Fitzroy Dawkins, Chuan Tian, Hanna Jean Khoury, Haris Ali, Michael C. Arbushites, Miguel-Angel Perales, Mark A. Schroeder
Publikováno v:
Blood. 132:601-601
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with high-risk or relapsed hematologic malignancies. Development of acute graft-vs-host disease (aGVHD) is a risk fac
Publikováno v:
Quality of Life Research. 22:2777-2786
To compare pain assessment questionnaires commonly used in advanced prostate cancer trials and to determine the psychometric characteristics and longitudinal relationships by contrasting questionnaire data from two international phase 2 trials.Scores
Autor:
C. H. Takimoto, Kenneth J. Pienta, Jean-Pascal Machiels, Yusri Elsayed, Mikhail Shkolnik, Susan Li, Johann S. de Bono, Fitzroy Dawkins, Simon J. Crabb, Shobha Seetharam, D. Schrijvers, Thomas A. Puchalski, Boris Alekseev
Publikováno v:
Investigational New Drugs. 31:760-768
Background CC-chemokine ligand 2 (CCL2) promotes tumor growth by angiogenesis, macrophage infiltration and tumor invasion, and distant metastasis. Carlumab (CNTO 888) is a human IgG1κ mAb with high affinity and specificity for human CCL2. Preclinica
Autor:
Fitzroy Dawkins, Kenneth H. Yu, Eric Van Cutsem, Edward W Greeno, Johanna C. Bendell, Eileen M. O'Reilly, Chung-Pin Li, Marcelo Garrido, Vaibhav Sahai, Manuel Hidalgo, Chris Verslype, Jason Clark, Ashwin Reddy Sama, Christopher James Walker, Teresa Macarulla, Herbert Hurwitz
Publikováno v:
Journal of Clinical Oncology. 35:343-343
343 Background: The JAK-STAT pathway plays a role in the pathogenesis of PC. In a phase 2 study, the JAK1/2 inhibitor Rux + C improved OS vs C alone in mPC pts with evidence of systemic inflammation. Methods: In two phase 3 studies, advanced/mPC pts